Effectiveness Modelling and Economic Evaluation of Primary HPV Screening for Cervical Cancer Prevention in New Zealand

Jie-Bin Lew1*, Kate Simms1, Megan Smith1, Hazel Lewis2, Harold Neal3, Karen Canfell1,4

1 Cancer Research Division, Cancer Council New South Wales, New South Wales, Australia, 2 Public Health Physician, Wellington, New Zealand, 3 National Screening Unit, Ministry of Health, Wellington, New Zealand, 4 School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia

* jiebin.lew@nswcc.org.au

Abstract

Background

New Zealand (NZ) is considering transitioning from 3-yearly cervical cytology screening in women 20–69 years (current practice) to primary HPV screening. We evaluated HPV-based screening in both HPV-unvaccinated women and cohorts offered HPV vaccination in New Zealand (vaccination coverage ~50%).

Methods

A complex model of HPV transmission, vaccination, cervical screening, and invasive cervical cancer was extensively validated against national population-based datasets. Sixteen potential strategies for HPV screening were considered.

Results

Most primary HPV strategies were more effective than current practice, for both unvaccinated women and cohorts offered vaccination. The optimal strategy for both groups was 5-yearly HPV screening in women aged 25–69 years with partial genotyping for HPV 16/18 and referral to colposcopy, and cytological triage of other oncogenic types. This is predicted to reduce cervical cancer incidence and mortality by a further 12–16% and to save 4–13% annually in program costs (excluding overheads). The findings are sensitive to assumptions about future adherence to initiating screening at 25 years.

Conclusion

Primary HPV screening with partial genotyping would be more effective and less costly than the current cytology-based screening program, in both unvaccinated women and cohorts offered vaccination. These findings have been considered in a review of cervical screening in NZ.
Cost-Effectiveness of Primary HPV Screening for Cervical Cancer in New Zealand

Introduction

The New Zealand (NZ) National Cervical Screening Programme (NCSP) was established in 1990 [1]. The programme recommends 3-yearly routine screening with liquid-based cytology (LBC) for 20–69 year-old women, with human papillomavirus (HPV) triage testing for low-grade (ASC-US/LSIL) cytology in women 30+ years [1], and a modified version of the Bethesda System is used for cytology classification. The NZ National HPV Immunisation Programme was introduced in September 2008, offering free HPV vaccine for females born in 1990 or later; school-based immunisation for 12–13 year old girls commenced in most regions in 2009 [2]. Three-dose coverage achieved by the program in cohorts born in 1991–2000 is approximately 48–56% nationwide [3].

Consideration of a transition to primary HPV testing for cervical screening in NZ has been prompted by the emergent international evidence on the increased effectiveness of primary HPV screening compared to cytology. Women who test negative for cervical HPV infection have a substantially lower risk of later developing high-grade cervical intraepithelial neoplasia (CIN 2/3 and CIN3+) [4,5,6,7] and cervical cancer [8] compared to women with a negative cytology result. Cost-effectiveness analyses in various settings have also found that screening with primary HPV testing is likely to be cost-effective, or even cost-saving, when compared to cytology-based screening [9,10,11]. The Netherlands, Australia and Italy are now implementing the transition to HPV screening. The Ministry of Health, Welfare and Sport of the Netherlands recently announced a review of the existing screening program and a plan to adopt primary HPV testing from January 2017 [12]. All cervical screening programs in Italy are scheduled to complete the transition to 5-yearly HPV screening in women aged 30/35 to 64 years based on the National Prevention Plan 2014–2018 [13]. Based on the findings of a systematic review and effectiveness modelling and economic evaluation, the National Cervical Screening Program in Australia will transition from May 2017 to 5-yearly primary HPV screening, using a test with partial genotyping for HPV 16/18 and reflex liquid-based cytology (LBC) triage for women with other oncogenic infection [14]. As a sentinel experience for programme change, Australia is also implementing a major trial of primary HPV screening in the partially HPV-vaccinated population, which is known as Compass (NCT02328872). A parallel pilot service evaluation project using primary HPV screening in NZ, known as ‘Compass NZ’ (ACTRN12614000714684) has also completed recruitment.

In this context, in 2015 New Zealand initiated a process of policy review of the NCSP to consider a potential transition to primary HPV screening. The aims, therefore, of the current study were: (1) to construct, calibrate and validate a complex model of HPV vaccination and cervical screening in NZ; (2) to determine, in collaboration with the NZ NCSP, a set of possible strategies (i.e. clinical management pathways) suitable to the NZ context using HPV as the primary screening test; (3) to evaluate the lifetime effects and costs associated with each of these strategies, in relation to current practice for cervical screening, in both vaccinated and unvaccinated cohorts, taking into account the levels of vaccine coverage achieved in NZ; and thus (4) to identify optimal future screening approaches in NZ in both vaccinated and unvaccinated women.

Methods

Construction, calibration and validation of a model of the National Cervical Screening Program in New Zealand

A dynamic model of HPV transmission and vaccination (implemented in Microsoft Visual Studio C++), coupled with a deterministic Markov model of the natural history of CIN and
cervical screening and invasive cervical cancer survival (implemented using TreeAge Pro 2014, TreeAge Software, Inc., MA, USA), was used to simulate cervical disease and screening in NZ. This model platform, adaptable to different settings, has been previously used to evaluate various cervical screening and follow-up management strategies in Australia, NZ and England [10,15,16,17,18,19,20,21]. Most recently, it has been used to evaluate primary HPV screening in both unvaccinated women and cohorts offered vaccination in England [9] and in Australia [10]; the Australian findings have underpinned the recent recommendations to transition to primary HPV screening in that country.

**Model of natural history of HPV, precancer and cervical cancer.** The natural history model incorporates different disease progression and regression rates for HPV 16 infections, HPV 18 infections and other oncogenic HPV infections (HPV OHR; any oncogenic HPV type but not type 16 or 18). The dynamic HPV transmission model, adapted from previous work, [9,22,23] takes into account the effect of the National HPV Immunisation Program [3] and was used to predict HPV incidence by single year of age over time in NZ. Due to the absence of local data on HPV prevalence in the general population, the predicted prevalence of all-oncogenic and type-specific HPV infections were calibrated to that observed in Australia [24] and the UK [25]. However, the model was also calibrated to the observed age-specific rate of histologically-confirmed high-grade lesions including AGC/AIS, cervical cancer incidence and cervical cancer mortality in NZ, taking into account of the effect of cervical screening and follow-up management (see section below). The proportion for each HPV type found in HPV-positive women diagnosed with histologically-confirmed high-grade lesions [26] and cervical cancer [27] were also calibrated to local data, although we assumed that all non-misclassified high-grade precancerous lesions and all cervical cancers were causally related to HPV infection, in line with international consensus [28]. The annual progression rate from CIN3 to asymptomatic localised cancer was modelled at an age-standardised rate of 1.1%, which is consistent with the available data [29].

**Model of current cervical screening, diagnosis and treatment in New Zealand.** Current practice (CP) for cervical screening within the NCSP was modelled based on existing clinical management guidelines [1]. Adherence to screening and follow-up recommendations was modelled in detail for each management recommendation and age group, using data on cumulative attendance over time from the NZ National Cervical Screening Program Register (NCSP-R) data. The test characteristics of LBC in the local program were informed by meta-analysis [30] and calibrated to the overall and age-specific rates of each grade of cytology (ASC-US, LSIL, ASC-H and HSIL) among screened women observed locally in NZ in 2010–11; resulting in a calibrated test sensitivity of 78.6% and a specificity of 94.3% for histologically-confirmed CIN 2 or worse (CIN2+) detection at an ASC-US cut-off in women aged 20–69 years. The modelled test sensitivity and specificity varies across age-groups due to the changes in mix of the women’s underlying health state by age. More information on the age-specific test sensitivity and specificity are provided in the supplementary document S1 Appendix. The test characteristics of HPV testing as a triage test for women with low-grade cytology outcomes (ASC-US/LSIL) and as a follow-up test after treatment of CIN2/3 were derived based on the findings of a meta-analysis [31] and were further calibrated to the age-specific HPV positive rate observed in NZ in 2012–13 [32,33,34,35].

We took a health services perspective, considering screening, diagnosis and treatment costs for the NZ government. All costs are presented in NZ dollars (1 NZD = 0.7305 USD, 25 May 2015) and were inflated to 2017/18 values. The costs were obtained from the NCSP with the costs of cervical cancer treatment further calibrated to achieve an average cost of $23,116 per cancer patient as reported in 2008/09 in NZ [36]. All costs excepting the cost of HPV testing were assumed to be the same in both current practice and in primary HPV testing strategies.
The unit cost of HPV test was assumed to be reduced from the current price of $43.56 to $35.00 in primary HPV screening strategies due to expected volume price breaks.

Because we have previously demonstrated in similar evaluations for Australia [10] and England [9] that the findings of evaluations of primary HPV testing are very sensitive to differing assumptions about quality-adjusted-life-year (QALY) weights, life-years (LYs) were considered as the primary outcome of the current analysis, QALYs were assessed as a secondary outcome using three sets of QALY weights—Set 1 assigned some disutility to the experience of being screened, even if the result was negative, Set 2 did not assign any disutility to the experience of being screened per se but assign high amount of disutility for having abnormal screening outcomes, and Set 3 did not assign any disutility to the experience of being screened per se but assigned a small disutility for having abnormal screening outcomes.

Further details of model structure, assumptions and the data sources are described in the supplementary document S1 Appendix.

Determination of strategies for the evaluation

A total of 16 primary HPV screening strategies, determined in a series of consultations with the NCSP and its Advisory Group, were modelled (see Table 1). The strategies can be categorised into four main groups (S1-4) which varied according to the screening and triage approach (primary HPV with cytology triage for all HPV-positive; primary HPV with partial genotyping; co-testing; or co-testing with partial genotyping) and each contained four sub-strategies (a-d) which according to whether only HPV screening was used in women 25+ or whether cytology screening was used in women 20–29 years with 'switch-over' to HPV screening in older women, and in the management of HPV-positive women. Fig 1 shows the detailed flowcharts for current practice and primary HPV screening strategy S1a, S2a, S3a and S4a as examples. Detailed flowcharts of all screening strategies are provided in the supplementary document S1 Appendix.

In the base case, primary HPV testing was assumed to have a test sensitivity of 96.4% and a specificity of 90.3% for CIN2+ detection in 20–69 years, consistent with the pooled absolute test sensitivity and specificity reported in a meta-analysis [31]. Compared to the calibrated LBC test characteristics in NZ, this has a relative sensitivity of 1.23 and a relative specificity of 0.96 for CIN2+ detection at an ASC-US+ threshold, which is consistent with the lower end of the meta-analysis findings [31], which is thus an appropriate, but favourable, assumption for cytology screening (i.e. current practice) in this evaluation.

The screening strategies were evaluated under two scenarios with respect to HPV vaccination. The 'unvaccinated scenario' assumed all women were unvaccinated, and thus this scenario tends to reflect outcomes in older cohorts. The 'vaccinated scenario' assumed women were offered HPV vaccination with uptake as observed in the cohort born in 1997 who were offered HPV vaccination at 12 years in 2009 through the HPV Immunisation Program [3] that commenced in late 2008. This cohort was selected in this evaluation on the basis that they would turn 20 years of age in 2017, and thus would be the first age group who would not be offered screening until age 25 if the current program were to change in that year. The 3-dose HPV vaccine coverage achieved in this cohort is 54% [3].

For the strategies that assumed screening starts at 25 years, in the base case we modelled a 'rapid uptake' at 25 years, which assumed an invitation was issued and that women currently starting screening before age 25 years would all have their first screening test at 25 years under the new recommendations. The compliance to a 5-yearly interval was derived by assuming the proportion of women have early re-screening, on-time screening and late re-screening remained similar to that observed under current practice in NZ (see supplementary document S1 Appendix for more details).
The outputs of the model included cumulative lifetime risk (CLR) and age-specific rates of cervical cancer incidence and mortality, cytology test outcomes and histology test outcomes from age 10 to 84 years. Age-standardised rate (ASR) of cervical cancer incidence and mortality were calculated assuming the World Health Organisation (WHO) population. The average lifetime number of screening/follow-up episodes and colposcopy examinations were calculated by accruing the number of screening/follow-up episodes and colposcopy examinations experienced between 20 and 84 years. We defined a screening/follow-up episode to be a

Table 1. List of primary HPV screening strategies evaluated.

| Strategy name | Age of screening starts | Screening test | Management for intermediate risk group* # |
|---------------|-------------------------|----------------|------------------------------------------|
| S1a           | 25                      | 5-yearly HPV test with cytology triage | Follow-up with co-testing in 12 months |
| S1b           | 25                      | 5-yearly HPV test with cytology triage | Immediate colposcopy |
| S1c           | 20                      | 3-yearly cytology screening | Follow-up with co-testing in 12 months |
| S1d           | 20                      | 3-yearly cytology screening | Immediate colposcopy |
| S2a           | 25                      | 5-yearly HPV testing with partial genotyping & cytology triage | Follow-up with HPV testing alone in 12 months |
| S2b           | 25                      | 5-yearly HPV testing with partial genotyping & cytology triage | Immediate colposcopy |
| S2c           | 20                      | 3-yearly cytology screening | Follow-up with HPV testing alone in 12 months |
| S2d           | 20                      | 3-yearly cytology screening | Immediate colposcopy |
| S3a           | 25                      | 5-yearly co-testing with cytology & HPV test | Follow-up with co-testing in 12 months |
| S3b           | 25                      | 5-yearly co-testing with cytology & HPV test | Immediate colposcopy |
| S3c           | 20                      | 3-yearly cytology screening | Follow-up with co-testing in 12 months |
| S3d           | 20                      | 3-yearly cytology screening | Immediate colposcopy |
| S4a           | 25                      | 5-yearly co-testing with cytology & HPV test with partial genotyping | Follow-up with HPV testing alone in 12 months |
| S4b           | 25                      | 5-yearly co-testing with cytology & HPV test with partial genotyping | Immediate colposcopy |
| S4c           | 20                      | 3-yearly cytology screening | Follow-up with HPV testing alone in 12 months |
| S4d           | 20                      | 3-yearly cytology screening | Immediate colposcopy |

* This group refers to women who test positive for HR HPV and low-grade cytology in S1a-d and S3a-d, and women who test positive to non-16/18 HR HPV and low-grade cytology in S2a-d and S4a-d.

# Women who test positive for HR HPV and negative cytology in S1a-d and S3a-d were referred to a 12 months follow-up with co-testing; women who test positive for non-16/18 HR HPV and negative cytology in S2a-d and S4a-d were referred to 12 months follow-up with HPV testing.

doi:10.1371/journal.pone.0151619.t001

Health, costs, and resource utilisation outcomes

The outputs of the model included cumulative lifetime risk (CLR) and age-specific rates of cervical cancer incidence and mortality, cytology test outcomes and histology test outcomes from age 10 to 84 years. Age-standardised rate (ASR) of cervical cancer incidence and mortality were calculated assuming the World Health Organisation (WHO) population. The average lifetime number of screening/follow-up episodes and colposcopy examinations were calculated by accruing the number of screening/follow-up episodes and colposcopy examinations experienced between 20 and 84 years. We defined a screening/follow-up episode to be a
Fig 1. Modelled screening pathways of (a) CP, (b) S1a, (c) S2a, (d) S3a and (e) S4a. Coloured boxes indicate variations in other sub-strategies assessed. HG—High-grade (including ASC-H and HSIL); HR HPV—high-risk HPV; LG—low-grade (including ASC-US and LSIL); Neg—Negative; OHR HPV—non-16/18 high-risk HPV

doi:10.1371/journal.pone.0151619.g001
cytology or HPV test that a woman has for the purpose of routine screening or as follow-up after either a previous abnormal screening result or treatment for a precancerous lesion; additional cytology or HPV tests that a women may have during colposcopy or treatment for a precancerous lesion are not counted as separate screening/follow-up episodes. The number of new cervical cancer cases, cervical cancer deaths, women detected with CIN2/3, and screening, diagnostic and treatment services associated with the NCSP in 2017 were estimated assuming the 2017 NZ population [38].

Determination of optimal strategy
The overall lifetime cost, LYs and QALYs associated with each strategy were calculated as the model output of cost, life-years and QALYs of the cohort accrued from 10 to 84 years and discounted at a rate of 3.5% p.a. from 20 years (the age of currently initiating screening). The total cost associated with the NCSP in 2017 was estimated assuming the 2017 NZ population [38]. The effectiveness and costs of each candidate strategy were considered and for strategies that were more effective than CP, we calculated the incremental cost-effectiveness ratio (ICER) compared to the next most effective strategy in order to rank the strategies in terms of their comparative cost-effectiveness in relation to each other.

Sensitivity analysis
Univariate sensitivity analysis was performed on a list of key model assumptions listed in Table 2 to assess the robustness of the model predictions.

Ethical considerations
The National Cervical Screening Programme Register data used to inform model parameters were de-identified. The Cancer Council NSW Human Research Ethics Committee approved the transfer of these data to the researchers and the New Zealand Ministry of Health approved their use in this modelled evaluation.

Results
Model calibration and validation
The calibrated model outcomes showed close correspondence with observed age-specific rates of HPV prevalence [24,25], HPV type distribution in women with HPV-positive histologically-confirmed disease or cervical cancer [26,27], histologically-confirmed high-grade abnormalities, cytology outcomes [39], overall age-specific cervical cancer incidence and mortality [40,41,42,43,44,45,46], and cancer stage distribution [47]. The model outputs for overall screening participation (given the detailed age and management specific adherence assumptions used as inputs) and cytology test performance were validated against recent data observed in NZ [39]. See supplementary document S1 Appendix for more detailed model calibration and validation outcomes.

Health, costs and cost-effectiveness outcomes

Health outcomes. In the NZ population of 2.3 million women aged <85 years in 2017, if current practice (CP) for screening was retained, a total of 160 new cervical cancer cases, 45 cervical cancer deaths and 4,038 women detected with histologically-confirmed high-grade were estimated to occur in the unvaccinated scenario; with 92 new cancer cases, 26 cancer deaths and 2,645 cases of histologically-confirmed high-grade disease in the vaccinated scenario (Table 3). The predicted ASRs for cervical cancer incidence and mortality were 9.1 and
### Table 2. Selected key model parameter assumptions.

| Model parameters                                                                 | Baseline assumption                                                                 | Sensitivity analysis range |
|----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|----------------------------|
|                                                                                  | Min                                                                                  | Max                        |
| Unsatisfactory rate of cytology                                                  | 1.17%                                                                               | 0.60%                      |
| Test accuracy of cytology for primary screening, in 20–69 years a,b                | Sensitivity: 78.6%; Specificity: 94.3%                                               | N/A                        |
|                                                                                  | N/A                                                                                 | N/A                        |
| Test accuracy of cytology for triaging women with positive HPV result, in 20–69 years a,b | Sensitivity: 78.7%; Specificity: 74.5%                                               | N/A                        |
| Test accuracy of HPV testing for primary screening, in 20–69 years b              | Sensitivity: 96.4%; Specificity: 90.3%                                               | Sensitivity: 95.1%; Specificity: 88.9% |
| Test accuracy of HPV testing for triaging women with ASC-US cytology result, in 20–69 years b,c | Sensitivity: 90.8%; Specificity: 72.6%                                               | Sensitivity: 89.5%; Specificity: 50.6% |
| Test accuracy of HPV testing for triaging women with LSIL cytology result, in 20–69 years b,c | Sensitivity: 94.1%; Specificity: 47.4%                                               | Sensitivity: 90.5%; Specificity: 24.6% |
| Test accuracy of HPV testing for follow-up women treated for HG CIN (TOC), in 20–69 years b | Sensitivity: 92.5%; Specificity: 82.7%                                               | Sensitivity: 85.1%; Specificity: 75.3% |
| Test accuracy of HPV partial genotyping among women test positive for oncogenic HPV infection | Perfect accuracy in detecting the present of HPV 16/18 infections (Alternative assumption 1) 10% of women infected with HPV 16/18 will be misclassified as infected with HPV OHR | (Alternative assumption 2) 10% of women tested false positive against all oncogenic type will be misclassified as infected with HPV 16/18 |
| Colposcopy positive rate                                                         | No CIN: 50.2%; CIN 1: 76.5%; CIN 2/3: 88.4%; Cancer: 100.0%                          | No CIN: 45.2%; CIN 1: 68.9%; CIN 2/3: 79.6%; Cancer: 100.0%  |
|                                                                                  | No CIN: 73.8%; CIN 1: 79.2%; CIN 2/3: 90.8%; Cancer: 100%                           | No CIN: 73.8%; CIN 1: 79.2%; CIN 2/3: 90.8%; Cancer: 100%  |
| Screening initiation for scenario assuming screening starts from 25 years (applicable only to scenarios assumed screening starts from 25 years) | Rapid screening uptake at age of 25<sup>a</sup> | Gradual uptake at age of 25<sup>a</sup> |
| Routine screening compliance (applicable only to scenarios assumed 5-yearly screening) | 5-yearly reminder-based | 5-yearly call-and-recall |
| Compliance to follow-up management                                               | Base case assumption                                                                | Overall compliance rate decreased by 10% |
|                                                                                  | Overall compliance rate decreased by 10%                                             | Overall compliance rate increased by 10% |
| Compliance to colposcopy referral                                                | Base case assumption                                                                | Overall compliance rate decreased by 10% |
|                                                                                  | Overall compliance rate decreased by 10%                                             | Overall compliance rate increased by 10% |
| Aggressiveness of CIN natural history                                            | Base case assumption calibrated to multiple targets (5% less aggressive)             | (5% more aggressive) A 5% relative increase in progression rate and decrease in regression rate for all CIN transition probabilities |
|                                                                                  | (5% more aggressive) A 5% relative increase in progression rate and decrease in regression rate for all CIN transition probabilities |
| Adjustment for ‘unmasking effect’ for HPV OHR type (application only to scenarios modelled the effect of HPV vaccination) | Base case assumption calibrated to a ~8% increase in OHR prevalence | No adjustment for ‘unmasking effect’ |
|                                                                                  | N/A                                                                                 | N/A                        |
| Cytology test cost                                                               | $30.19                                                                              | $25.00                     |
| HPV test cost under current practice strategies                                   | $43.56                                                                              | N/A                        |
| HPV test cost (under primary HPV screening strategies)                            | $35.00                                                                              | $30.00                     |
| Vaccination coverage                                                             | Coverage rate for female based on 3-dose data                                      | Coverage rate for female based on 2-dose data |
| Discounted rate                                                                  | 3.5%                                                                                | 1.0%                       |
|                                                                                  | 5.0%                                                                                |                            |

- **CIN**: Cervical intraepithelial neoplasia; **HG**: high-grade; **HPV OHR**: oncogenic HPV type other than HPV 16 or 18; **TOC**: Test-of-cure;
- **a** Cut-off at ASC-US threshold;
- **b** For CIN2-detection;
- **c** Same test accuracy was modelled for HPV triage testing for women with both ASC-US and LSIL cytology result. Differences in the test sensitivity and specificity were due to the differences in the mix of underlying health states between women with ASC-US and LSIL cytology result;
- **d** Assume women who have had their first screening test at age ≤ 25 years under current practice would all have their first screening test at age 25 years in the scenario assuming screening starts from 25 years;
- **e** Assume a gradual screening initiation in 25–29 years. The proportion of women who have had their first screening test by the age of 30 of the scenario was assumed to be the same as the proportion assumed for current practice.

<sup>DOI:10.1371/journal.pone.0151619.t002</sup>
Table 3. Model-predicted cervical cancer incidence, cervical cancer death, histologically-confirmed CIN2/3 and cost associated with screening program.

| Strategies | Cervical cancer incidence | Cervical cancer death | Number of CIN2/3 detected | Total cost associated with screening program a,b |
|------------|---------------------------|-----------------------|---------------------------|-----------------------------------------------|
|            | CLR a | Cases a,b | ASR c | % change in ASR d | CLR a | Cases a,b | ASR c | % change in ASR d | | Cost (in SM) | Difference compare to CP (a change) |
| Unvaccinated scenario |
| CP        | 0.63% | 160 | 9.1 | - | 0.20% | 45 | 1.5 | - | 4,038 | $31.7 M | - |
| S1a       | 0.64% | 161 | 9.1 | 0.1% | 0.20% | 45 | 1.5 | 0.3% | 3,704 | $28.7 M | -$3.0 M (-9%) |
| S1b       | 0.57% | 144 | 8.1 | -11.1% | 0.18% | 40 | 1.3 | -11.9% | 3,998 | $31.1 M | -$0.6 M (-2%) |
| S1c       | 0.66% | 167 | 9.4 | 3.3% | 0.21% | 48 | 1.6 | 5.0% | 3,962 | $29.3 M | -$2.4 M (-8%) |
| S1d       | 0.62% | 157 | 8.9 | -2.1% | 0.20% | 44 | 1.5 | -1.9% | 4,056 | $30.5 M | -$1.1 M (-4%) |
| S2a       | 0.56% | 140 | 7.7 | -15.2% | 0.18% | 39 | 1.3 | -15.6% | 3,995 | $30.4 M | -$1.3 M (-4%) |
| S2b       | 0.54% | 136 | 7.5 | -17.3% | 0.17% | 38 | 1.2 | -18.0% | 4,118 | $32.2 M | $0.5 M (2%) |
| S2c       | 0.62% | 157 | 8.9 | -2.1% | 0.20% | 44 | 1.5 | -2.1% | 4,012 | $29.5 M | -$2.1 M (-7%) |
| S2d       | 0.60% | 154 | 8.7 | -3.7% | 0.19% | 43 | 1.4 | -4.0% | 4,069 | $30.7 M | -$1.0 M (-3%) |
| S3a       | 0.63% | 158 | 8.9 | -2.1% | 0.20% | 45 | 1.5 | -1.3% | 3,785 | $36.4 M | $4.7 M (15%) |
| S3b       | 0.57% | 143 | 7.9 | -12.6% | 0.18% | 40 | 1.3 | -12.6% | 4,069 | $38.7 M | $7.0 M (22%) |
| S3c       | 0.65% | 165 | 9.3 | 2.0% | 0.21% | 47 | 1.6 | 3.9% | 3,992 | $35.5 M | $3.8 M (12%) |
| S3d       | 0.61% | 155 | 8.8 | -3.1% | 0.20% | 44 | 1.5 | -2.5% | 4,082 | $36.7 M | $5.0 M (16%) |
| S4a       | 0.54% | 135 | 7.5 | -17.6% | 0.17% | 38 | 1.2 | -17.7% | 4,073 | $38.3 M | $6.6 M (21%) |
| S4b       | 0.53% | 132 | 7.3 | -19.5% | 0.17% | 37 | 1.2 | -19.3% | 4,191 | $40.0 M | $8.4 M (26%) |
| S4c       | 0.60% | 152 | 8.7 | -4.6% | 0.19% | 43 | 1.4 | -4.6% | 4,055 | $35.9 M | $4.3 M (13%) |
| S4d       | 0.59% | 150 | 8.5 | -6.1% | 0.19% | 42 | 1.4 | -6.4% | 4,109 | $37.1 M | $5.4 M (17%) |
| Vaccinated scenario |
| CP        | 0.36% | 93  | 5.2 | - | 0.12% | 26 | 0.8 | - | 2,645 | $25.9 M | - |
| S1a       | 0.37% | 93  | 5.2 | 0.2% | 0.12% | 26 | 0.9 | 0.3% | 2,401 | $22.5 M | -$3.5 M (-13%) |
| S1b       | 0.33% | 83  | 4.6 | -10.9% | 0.10% | 23 | 0.7 | -11.8% | 2,616 | $24.6 M | -$1.3 M (-5%) |
| S1c       | 0.38% | 96  | 5.4 | 3.5% | 0.12% | 27 | 0.9 | 5.3% | 2,579 | $23.4 M | -$2.7 M (-10%) |
| S1d       | 0.35% | 90  | 5.1 | -2.2% | 0.11% | 25 | 0.8 | -2.0% | 2,655 | $24.5 M | -$1.5 M (-6%) |
| S2a       | 0.33% | 83  | 4.6 | -11.7% | 0.11% | 23 | 0.7 | -11.9% | 2,527 | $22.7 M | -$3.2 M (-12%) |
| S2b       | 0.32% | 79  | 4.4 | -15.7% | 0.10% | 22 | 0.7 | -16.5% | 2,667 | $24.7 M | -$1.2 M (-5%) |
| S2c       | 0.36% | 92  | 5.2 | -0.3% | 0.12% | 26 | 0.9 | 0.3% | 2,595 | $23.0 M | -$3.0 M (-11%) |
| S2d       | 0.35% | 89  | 5   | -3.3% | 0.11% | 25 | 0.8 | -3.4% | 2,657 | $24.3 M | -$1.7 M (-6%) |
| S3a       | 0.36% | 91  | 5.1 | -2.1% | 0.12% | 26 | 0.8 | -1.4% | 2,463 | $30.3 M | $4.3 M (17%) |
| S3b       | 0.33% | 82  | 4.5 | -12.5% | 0.10% | 23 | 0.7 | -12.6% | 2,672 | $32.3 M | $6.4 M (25%) |
| S3c       | 0.38% | 95  | 5.3 | 2.1% | 0.12% | 27 | 0.9 | 4.1% | 2,604 | $29.5 M | $3.6 M (14%) |
| S3d       | 0.35% | 89  | 5   | -3.3% | 0.11% | 25 | 0.8 | -2.7% | 2,677 | $30.7 M | $4.8 M (18%) |
| S4a       | 0.32% | 81  | 4.5 | -14.1% | 0.10% | 23 | 0.7 | -13.9% | 2,587 | $30.6 M | $4.7 M (18%) |
| S4b       | 0.31% | 77  | 4.3 | -17.8% | 0.10% | 21 | 0.7 | -18.2% | 2,732 | $32.5 M | $6.6 M (25%) |
| S4c       | 0.35% | 90  | 5.1 | -2.7% | 0.11% | 25 | 0.8 | -2.0% | 2,626 | $29.4 M | $3.4 M (13%) |
| S4d       | 0.34% | 87  | 4.9 | -5.4% | 0.11% | 24 | 0.8 | -5.5% | 2,686 | $30.6 M | $4.6 M (18%) |

ASR- age-standardised rate; CLR- cumulative lifetime risk; a 0–84 years
b Assuming 2017 New Zealand female population
c Rate per 100,000 women in 20–69 years, assuming WHO population
d Compared to value predicted for CP

doi:10.1371/journal.pone.0151619.t003
1.5 per 100,000 women aged 20–69 years, respectively in the unvaccinated scenario, and 5.2 and 0.8, respectively in the vaccinated scenario. The predicted CLR of cervical cancer incidence and of cervical cancer mortality were 0.63% and 0.20%, respectively in the unvaccinated scenario, and 0.36% and 0.12%, respectively in the vaccinated scenario.

The relative effectiveness of each primary HPV screening strategy in relation to CP was similar in both unvaccinated and vaccinated scenarios. Twelve out of the sixteen primary HPV strategies were predicted to be associated with a decrease (of 2–20%) in cervical cancer incidence and mortality. Strategies varied in terms of their impact on the number histologically-confirmed high-grade cases, ranging from a +/-7% difference compared to CP (Table 3).

Partial genotyping strategies (S2 and S4 strategy groups) were associated with a 1–16% relative decrease (unvaccinated scenario: 2–16%; vaccinated scenario:1–13%) in cervical cancer incidence and mortality when compared to the equivalent non-partial genotyping strategies (S1 and S3 strategy groups); HPV and cytology co-testing strategies (S3 and S4 strategy groups) were associated with a modest (<1–3%) relative decrease in both scenarios when compared to the equivalent non-co-testing strategies (S1 and S2 strategy groups).

Within each strategy group, strategies assuming primary HPV screening starting at age 25 years (strategy sub-groups a and b) were predicted to be associated with a 3–15% relative decrease in cancer incidence and mortality when compared to the equivalent ‘switch-over’ strategy (strategy sub-groups c and d); strategies that refer ‘intermediate risk’ women to immediate colposcopy (strategy sub-groups b and d) were predicted to be associated with a 2–12% relative reduction in both scenarios when compared to the equivalent strategies that referring ‘intermediate risk’ women to 12 months follow-up (strategy sub-groups a and c). However, this difference was minimised in partial genotyping strategies, where the relative difference was only 2–5% (since the highest risk HPV16/18 positive women are referred directly to colposcopy in such strategies), compared to 5–12% in strategies without partial genotyping.

Compared to CP, starting screening at 25 years with primary HPV testing (strategy sub-groups a and b) was predicted to be associated with a higher cancer incidence rate in 25–29 year-old women (the first 5 years after screening begins) but a significantly lower rate in 30+ years (Fig 2). Partial genotyping strategies were estimated to have a lower cervical cancer incidence and mortality rates in all ages compared to strategies that do not employed partial genotyping. The ‘switch-over’ strategies were estimated to have a similar rate to CP at all ages.

Costs. Screening according to current practice is predicted to cost $31.7M to the NZ government in 2017 (unvaccinated) and $25.9M (vaccinated) (Table 3). This includes cervical screening, follow-up, and treatment for precancerous lesions and cancer. Compared to CP, primary HPV with cytology triage (S1 and S2) were predicted to be associated with a 3–12% decrease in costs but HPV and cytology co-testing strategies (S3 and S4) were predicted to be associated with a 12–26% increase in costs.

Cost-effectiveness. All strategies assuming primary HPV testing (S1 and S2 groups), were more effective than CP, and all except S2b were also cost-saving. All co-testing strategies (S3 and S4 groups) were both more effective and more costly than CP. Fig 3 shows the cost-effectiveness planes for the unvaccinated and the vaccinated scenario. We could not follow usual practice for deriving ICERs referenced to CP as the comparator, since some of the new strategies considered were both more effective and more cost-saving than CP. Therefore, for the current analysis, we did not consider CP as the comparator and included only the strategies that were more effective than CP. In this modified ICER analysis (which thus requires careful interpretation), S2a was the only strategy that was associated with an ICER that was below the $20,000–$50,000 per life-year saved indicative willingness-to-pay threshold for NZ in the analysis in both scenarios. This strategy is also a cost-saving strategy (more effective and less costly) when compared to current practice.
Fig 2. Estimated age-specific of cervical cancer incidence rate and cervical cancer mortality rate for all strategies.

doi:10.1371/journal.pone.0151619.g002
Supplementary cost-effectiveness analyses were undertaken using health utilities to incorporate the effect on morbidity as well as mortality. Findings varied widely with the different utility sets. Strategy S2a was predicted as the most cost-effective (and cost-saving) strategy in both the unvaccinated and vaccinated scenarios when QALY weights set 1 and 3 were assumed; all primary HPV screening strategies were predicted to be less effective than current practice when QALY weights set 2 was assumed. Detailed outcomes of the supplementary analysis are provided in the supplementary document S1 Appendix.

Resource utilisation

Fig 4a–4e shows the estimated number of cytology tests, HPV tests, women undergoing colposcopy examination, women having histology and women having treatment for precancerous lesion, assuming the female population predicted for NZ in 2017. Under CP management, approximately 28,800 women were estimated to undergo colposcopy examination and 11,800 women to have at least one histology evaluation in the unvaccinated scenario; in the vaccinated scenario, the numbers reduced to 21,000 and 8,600, respectively. Many of the primary HPV screening strategies were predicted to be associated with an increase in number of colposcopy examinations and histology evaluations in the unvaccinated scenario but in the vaccinated population the partial genotyping strategy S2a would not result in any substantial change in colposcopies.

About 5,020 women in the unvaccinated scenario and 3,350 women in vaccinated scenario were estimated to undergo treatment for precancer under CP; most primary HPV screening
strategies would result in a broadly similar number of women undergoing treatment (unvaccinated scenario: range 4,560–5,220; vaccinated scenario: range 2,980–3,440).

**Lifetime numbers of screening/follow-up episodes and colposcopies**

Under CP screening management, given the adherence assumptions used, a woman was predicted to experience 14.1 screening and/or follow-up episodes on average in her lifetime in the unvaccinated scenario and 14.0 episodes in the vaccinated scenario. This number will reduce to an average of 9.7 (unvaccinated scenario: 9.6–9.9; vaccinated scenarios: 9.4–9.7) episodes for primary HPV screening strategies screening starting from age 25 years (sub-strategies a and b), and to an average of 11.0 (unvaccinated: 11.0–11.2 episodes; unvaccinated scenario: 10.8–11.0) episodes for the ‘switch-over’ strategies (sub-strategies c and d) (Fig 5). On average, a woman was estimated underwent 1.0 colposcopy examination in her lifetime in the unvaccinated scenario and 0.7 examinations in the vaccination scenarios under CP screening management. The number increased in most of primary HPV screening strategies (unvaccinated scenario: 1.0–1.3; vaccinated scenarios: 0.7–0.9).
Number of precancer treatments per cervical cancer case prevented

Fig 6 compares the number of cervical cancer cases with the number of women who received treatment for precancer predicted for each strategy. There are six primary HPV screening strategies in the no vaccination scenario and eight strategies in the vaccinated scenario predicted to be associated with fewer cervical cancer cases and fewer women treated for precancer lesions than CP. Seven strategies in the no vaccination scenario and four strategies in the vaccinated scenario were associated with fewer cervical cancer cases but more of women treated for precancer lesions than CP. Among these scenarios, the number of additional treatments required per cancer case prevented ranged from 1.6–11.6 and 3.1–11.6, respectively (Fig 6).

Sensitivity analysis

Univariate sensitivity analysis was conducted for S2a and S2c in both unvaccinated and vaccinated scenarios. The predicted costs were found to be sensitive to the assumptions made for the cytology test cost, the screening initiation patterns, test characteristics of HPV test for primary screening or for triage testing on women with low-grade cytology results (which changes the predicted comparator outcomes), the cost of HPV testing, the accuracy of specific HPV partial genotyping outcomes and the aggressiveness of natural history in both scenarios. For S2a, the predicted life-years were found to be sensitive to the assumptions made for the aggressiveness of natural history (although this has been extensively calibrated over time for the model platform), and adherence to the recommendation to initiate screening at age 25 years (i.e. for most women to initiate screening at or close to that age and not later). Increased test sensitivity for both LBC as a triage test for women with a positive HPV test result and HPV as a triage test for women with low-grade cytology outcome were found to have minimal impact on the cost and life-years estimated for S2a. The detailed outcomes of the sensitivity analysis are provided in the supplementary document S1 Appendix.

Discussion

We have performed a comprehensive health and economic evaluation of primary HPV testing for cervical cancer screening in New Zealand, which takes into account the impact of a national
HPV vaccination program in that country. In this analysis, we found broad similarities in the relative outcomes between alternative screening strategies when considering unvaccinated women and women offered vaccination. Most (but not all) of the primary HPV screening strategies we considered were predicted to be more effective in reducing cancer incidence and mortality compared to current screening practice. Many of the primary HPV screening strategies, with the exception of co-testing, were also predicted to be less costly than current practice. In the cost-effectiveness analysis, primary screening with partial genotyping for women aged 25–69 years, with direct referral of HPV16/18 positive women to colposcopy and LBC triage for women positive for other oncogenic types with 12 month follow-up for LBC negative and low-grade results in that group (Strategy S2a) was identified as both more effective and also cost saving compared to current practice, and in comparative incremental analysis was the most cost-effective strategy in both scenarios. This strategy was predicted to be associated with a further 12–16% reduction in cervical cancer incidence and mortality and a saving of $NZ1.3 M—$3.2 M (4–12%) of the total program cost of screening compared to current practice. A variation of this strategy, where women testing positive for other (non-HPV16/18) oncogenic types but who had low-grade cytology were referred directly for colposcopy (Strategy S2b), was marginally more effective, but not cost-effective (> $160,000/LYS) compared to a $20,000-$50,000 saving.
per life-year saved indicative willingness-to-pay threshold in New Zealand (where the upper end reflects the approximate GDP per capita in March 2015).

The three QALY weight sets assessed in the supplementary analysis of this study were obtained from three different studies [48,49,50] and the outcome varied significantly when different sets were assumed. Similar to the findings of previous evaluations [9,10], we found that the model’s findings are very sensitive to differing assumptions about QALY weights. Therefore, life-years were considered as the primary outcome of the current analysis and QALYs were assessed as a secondary outcome. The QALY-related findings thus need to be interpreted keeping in mind the significant variation in QALY weights found by different studies [48,49,50]. More study on the health utilities related to cervical screening is required; focus groups or other methods could be used to perform more detailed assessments of the quality of life utilities associated with the experience of having a cervical sample taken (and waiting for the result), of having an abnormal cytology test or positive HPV test, and of being referred for colposcopy and having treatment and post-treatment surveillance.

The current evaluation was performed on behalf of the National Cervical Screening Programme (NCSP) and overseen by the programme’s Advisory Group. This was done in the context of the recent announcement by the Australian government that it will transition to 5-yearly HPV screening in women aged 25–70 years by May 2017; the effectiveness modelling and economic evaluation to support that decision in Australia harnessed the same modelled platform and methods as for the current evaluation in New Zealand [10]. As for our prior evaluation in Australia, we found that the optimal strategy for primary HPV screening strategies would be both more effective and cost saving when compared to current screening practice, reducing cervical cancer incidence and mortality in New Zealand by a further 12–16% compared to current levels. A strength of the evaluation is that it used a comprehensive and calibrated model of cervical screening, based on detailed clinical management guideline recommendations, taking into account the observed screening behaviour. We conducted detailed evaluations of a wide range of primary HPV testing management options and these findings will inform policy makers of the potential benefit as well as the impact on resource utilisation associated with primary HPV testing in NZ.

A limitation of this study was that a number of influential parameters related to future screening practices, by necessity, were based on assumptions. However, these assumptions had been extensively discussed with in-country experts at the NCSP. For the primary HPV testing strategies, we assumed ~80% of women will attend for their first screening test at 25 years (based on the current uptake rate observed in women aged < 25 years) and that the compliance rate to a 5-year screening interval recommendation will be consistent with that currently observed for the recommended 3-year interval, including limited early re-screening. After consultation, we also assumed the cost of HPV test would reduce to $35 per test when HPV test was used as the primary screening test (assuming a lower unit test cost could be negotiated with a larger volume of tests being purchased). The sensitivity analysis has found that the cost outcomes are sensitive to this assumption and thus this is a prime consideration for decision-makers in the transition to primary HPV screening. However, the optimal strategy for HPV screening with partial genotyping is still predicted to be cost saving compare to current practice when assuming HPV test cost was $40 per test in sensitivity analysis.

This evaluation was conducted using assumptions that were favourable for cytology testing and conservative with respect to primary HPV testing. Specifically, the base case assumptions for HPV test characteristics were derived such that the relative test sensitivity and specificity (compared to base case cytology test characteristics) was consistent with the lower end of the 95% CI of the findings of a major meta-analysis [31]—that is, assumed the minimum improvement in the screening test sensitivity and maximum loss in test specificity when HPV test was
used for screening compared to cytology. Additionally, the potential degradation in cytology performance due either to HPV 16/18 depletion (reduced cytological abnormalities) and its subsequent impact on cytology accuracy (reduced PPV for CIN2/3) or cytologist de-training effects [48] were not accounted for in the vaccinated scenario in this evaluation. Furthermore, the differential test accuracy for glandular lesions of cytology and HPV test, which is expected to be relatively higher for HPV testing, was not modelled in this evaluation. Finally, the modelled cost of HPV test under primary HPV screening strategies ($NZ 35.00 per test) was conservatively assumed to be modestly higher than the cost cytology test ($NZ 30.19) based on the advice of the NCSP. The modelled strategies would be associated with a greater cost-saving if the cost of the HPV test was lower than the current cost of cytology test. Therefore, our favourable findings with respect to primary HPV screening can be considered to be based on conservative ‘reasonable worst case’ assumptions for HPV screening effectiveness.

We found that most of the primary HPV screening strategies were predicted to increase the number of women requiring access to diagnostic services, if the impact of vaccination is not considered. This finding implies that the colposcopy referral and histology evaluation rates may increase initially after a transition to primary HPV screening but are expected to drop over time as cohorts offered vaccination age and enter the new HPV screening program. However, it should be noted that the current estimates represent ‘steady state’ outcomes and transitional fluctuations in test volumes and referral rates would be expected after the transition of the screening program.

We found that 5-yearly primary HPV screening would be more effective and cost-saving compared to the current 3-yearly cytology screening program in NZ, and that managing women based on HPV partial genotyping was a highly effective, and the most cost-effective, option. We also found that co-testing with cytology is not cost-effective. These findings are consistent with the results of similar modelled evaluations conducted for England and Australia [9,10].

It is notable that, although NZ and Australia have differing recommendations for current practice for cervical cytology screening (i.e. 3-yearly screening in NZ vs. 2-yearly in Australia), the optimal strategy identified in this evaluation for NZ (HPV testing with partial genotyping for HPV16/18 and LBC triage for OHR HPV types) is very similar to the proposed pathway for primary HPV screening identified in the National Cervical Screening Program Renewal for Australia [49]. It also closely corresponds to one arm of the Compass trial, a large scale randomised controlled trial of primary HPV screening commenced in Australia in 2013 (ACTRN12613001207707) and the main trial of 121,100 women has begun in 2014 (NCT023328872); the trial was extended to NZ in 2014.

The assessed primary HPV screening strategies were determined in a series of consultations with the NCSP and its Advisory Group, and were modelled in the context of New Zealand, which has an effective cervical screening program that provides 3-yearly routine screening using cytology test with a high test sensitivity (~79% for CIN2+ detection) for 20–69 years. Although the optimal screening strategy identified by this study is also similar to the proposed pathway identified in the National Cervical Screening Program Renewal for Australia [49], some of the study specific outcomes may not be applied directly to some other country setting. For example, 5-yearly primary HPV screening may be associated with a greater health benefit gained but not cost saving in countries with cytology screening programs that recommend less frequent screening (i.e. 5-yearly) or which use a cytology test with lower test sensitivity; countries with cytology screening programs that recommend more frequent screening (i.e. annual or biennial) or which use a cytology test with higher test sensitivity may find a lesser health benefit gained associated with 5-yearly primary HPV testing. The acceptability of the various strategies, and in particular the management of women with non-16/18 HPV positive and
low-grade cytology result is likely to depend not only evidence generated from carefully con-
ducted modelled evaluations but also to some extent on country specific issues and consider-
ations which include the ‘starting point’ i.e. current acceptable management in different
situations.

NZ had a challenging history with respect to the original introduction and development of
cervical screening [50,51]. Therefore, changes to the program will involve wide consultation
with women and providers. The NZ service evaluation experience represented by the extension
of Compass will play a role in this process- Compass NZ (ACTRN12614000714684) has
recruited five hundred 25–64 year-old women presenting for cervical screening for 5-yearly
HPV screening with partial genotyping for HPV 16/18, to assess feasibility of this approach via
participant acceptability, promoting GP, nurse and colposcopist education, and facilitating lab-
oratory implementation. Since Compass NZ utilises the same pathway for primary HPV
screening as that identified in this modelled analysis as the optimal approach, it represents a
practical experience of primary HPV screening with this pathway before its implementation in
NZ.

Conclusion

We predict that primary HPV screening with genotyping for HPV16/18 will be both more
effective and less costly than the current program for 3-yearly cytology-based screening in NZ,
in both unvaccinated women and in cohorts offered vaccination. These findings are in accord-
dance with modelled evaluations for Australia and England and are consistent with the data
from large scale international trials of primary HPV screening. Any change in national policy
will involve extensive public consultation and will take into consideration broader criteria
beyond cost-effectiveness.

Supporting Information

S1 Appendix. Supplementary materials.
(DOCX)

Acknowledgments

A component of the work for this evaluation was conducted when the authors Jie-Bin Lew,
Megan Smith, Kate Simms and Karen Canfell were based at The University of New South
Wales, Australia. We thank other members of the working group of Cancer Screening Group
for their support in the project development for this study, particularly Yoon-Jung Kang,
Xiang-Ming Xu and Robert Walker. We thank the peer reviewers and Dr. Giorgi Kvizhinadze
and Professor Tony Blakely for very useful review of a draft version of this paper.

Author Contributions

Conceived and designed the experiments: JBL KS HL HN KC. Performed the experiments:
JBL KS MS KC. Analyzed the data: JBL KS MS KC. Contributed reagents/materials/analysis
tools: JBL KS MS KC. Wrote the paper: JBL KC MS KS.

References

1. National Screening Unit (2008) Guidelines for Cervical Screening in New Zealand: Incorporating
the management of women with abnormal cervical smears. Wellington: National Screening Unit, Ministry
of Health.
2. Ministry of Health (2014) History of the HPV immunisation programme. Available: http://www.health.govt.nz/our-work/preventative-health-wellness/immunisation/hpv-immunisation-programme/history-hpv-immunisation-programme. Accessed 23 September 2015.

3. Ministry of Health (2014) HPV immunisation programme. [updated 27 June 2014] Available: http://www.health.govt.nz/our-work/preventative-health-wellness/immunisation/hpv-immunisation-programme. Accessed 17 February 2015.

4. Elfstrom KM, Smelov V, Johansson AL, Eklund C, Naucler P, Arneheim-Dahlstrom L, et al. (2014) Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. Br J Cancer 348: g130. doi: 10.1136/bmj.g130 PMID: 24435414

5. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla P, Del MA, et al. (2010) Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 11: 249–257. doi: 10.1016/S1470-2045(09)70360-2 PMID: 20089449

6. Kitchener HC, Gilham C, Sargent A, Bailey A, Albrow R, Roberts C, et al. (2011) A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: Extended follow up in the ARTISTIC trial. Eur J Cancer 47: 864–871. doi: 10.1016/j.ejca.2011.01.008 PMID: 21334200

7. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. (2008) Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. Br J Cancer 337: a1754. doi: 10.1136/bmj.a1754 PMID: 18852164

8. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, et al. (2014) Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383: 524–532. doi: 10.1016/S0140-6736(13)62218-7 PMID: 24192252

9. Kitchener HC, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, et al. (2014) The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. Health Technol Assess 18: 1–196.

10. Lew JB, Simms K, Smith MA, Kang YK, Xu XM, Caruana M, et al. (2014) National Cervical Screening Program Renewal: Effectiveness modelling and economic evaluation in the Australian setting (Assessment Report). MSAC application number 1276. Canberra: Department of Health.

11. Burger EA, Ortendahl JD, Sy S, Kristiansen IS, Kim JJ (2012) Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway. Br J Cancer 106: 1571–1578. doi: 10.1038/bjc.2012.94 PMID: 22441643

12. National Institute for Public Health and the Environment MoH, Welfare and Sport. (2014) Cervical cancer screening in the Netherlands. [updated 21/01/2014] Available: http://www.rivm.nl/en/Documents_and_publications/Common_and_Present/Newsmessages/2014/Cervical_cancer_screening_in_the_Netherlands. Accessed 21 January 2015.

13. Ministero della Salute (2014) Piano Nazionale di Prevenzione 2014–2018. Available: http://www.salute.gov.it/imgs/C_17_pubblicazioni_2286_allegato.pdf. Accessed 12/02/2016

14. Australian Government Department of Health (2014) National Cervical Screening Program Renewal. [updated 15/5/2014] Available: http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/overview-of-the-renewal. Accessed 21 January 2015 2015.

15. Creighton P, Lew JB, Clements M, Smith M, Howard K, Dyer S, et al. (2010) Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years. BMC Public Health 10: 734. doi: 10.1186/1471-2458-10-734 PMID: 21110881

16. Canfell K, Barnabas R, Patnick J, Beral V (2004) The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. Br J Cancer 91: 530–536. PMID: 15266332

17. Medical Services Advisory Committee (2009) Automation Assisted and Liquid Based Cytology for Cervical Cancer Screening. MSAC reference 1122, Assessment report. Canberra: Australian Government Department of Health.

18. Medical Services Advisory Committee (2009) Human Papillomavirus Triage Test For Women With Possible or Definite Low-Grade Squamous Intraepithelial Lesions. MSAC reference 39, Assessment report. Canberra: Australian Government Department of Health.

19. Canfell K, Shi JF, Lew JB, Walker R, Zhao FH, Simonella L, et al. (2011) Prevention of cervical cancer in rural China: Evaluation of HPV vaccination and primary HPV screening strategies. Vaccine 29: 2487–2494. doi: 10.1016/j.vaccine.2010.12.085 PMID: 21211586

20. Legood R, Smith MA, Lew JB, Walker R, Moss S, Kitchener H, et al. (2012) Cost effectiveness of human papillomavirus test of cure after treatment for cervical intraepithelial neoplasia in England: economic analysis from NHS Sentinel Sites Study. BMJ 345.
21. Lew J-B, Howard K, Gertig D, Smith M, Clements M, Nickson C, et al. (2012) Expenditure and resource utilisation for cervical screening in Australia. BMC Health Services Research 12: 446. doi: 10.1186/1472-6963-12-446 PMID: 23216968

22. Smith MA, Canfell K, Brotherton JM, Lew JB, Barnabas RV (2008) The predicted impact of vaccination on human papillomavirus infections in Australia. Int J Cancer 123: 1854–1863. doi: 10.1002/ijc.23633 PMID: 18635653

23. Smith MA, Canfell K (2014) Incremental benefits of male HPV vaccination: Accounting for inequality in population uptake. PLoS One 9.

24. Garland SM, Brotherton JM, Condon JR, McIntyre PB, Stevens MP, Smith DW, et al. (2011) Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Med 9: 104. doi: 10.1186/1471-2334-9-104 PMID: 21910918

25. Kitchener HC, Almonte M, Wheeler P, Desai M, Gilham C, Bailey A, et al. (2006) HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 95: 56–61. PMID: 16773068

26. Simonella L, Lewis H, Smith M, Neal H, Bromhead C, Canfell K (2013) The prevalence of type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand. BMC Infect Dis 13.

27. Sykes P, Gopala K, Tan AL, Kenwright D, Petrich S, Moliën A, et al. (2014) Type distribution of human papillomavirus among adult women diagnosed with invasive cervical cancer (stage 1b or higher) in New Zealand. BMC Infect Dis 14: 374. doi: 10.1186/1471-2334-14-374 PMID: 25000939

28. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2009) A review of human carcinogens. Part B: Biological agents. Chapter 11: Human Papillomaviruses. Lyon, France: IARC.

29. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. (2008) Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncology 9: 425–434. doi: 10.1016/S1470-2045(08)70103-7 PMID: 18407790

30. Arbyn M, Bergeron C, Klinkhammer P, Martin-Hirsch P, Siebers AG, Bulten J (2008) Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstetrics & Gynecology 111: 167–177.

31. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. (2012) Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30 Suppl 5: F88–99. doi: 10.1016/j.vaccine.2012.06.095 PMID: 23199969

32. Smith M, Walker R, Canfell K (2013) National Cervical Screening Programme Monitoring Report Number 37. Wellington, NZ: National Screening Unit.

33. Smith M, Walker R, Canfell K (2014) National Cervical Screening Programme Monitoring Report Number 38. Wellington, NZ: National Screening Unit.

34. Smith M, Walker R, Canfell K (2014) National Cervical Screening Programme Monitoring Report Number 39. Wellington, NZ: National Screening Unit.

35. Smith M, Walker R, Canfell K (2014) National Cervical Screening Programme Monitoring Report Number 40. Wellington, NZ: National Screening Unit.

36. Ministry of Health (2011) The Price of Cancer: The public price of registered cancer in New Zealand. Wellington: Ministry of Health.

37. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R, Inoue M (2001) Age standardization of rates: A new WHO standard. Geneva: World Health Organization.

38. Statistics New Zealand (2013) National population projections: 2011(base) -2061. Available: http://nzdotstat.stats.govt.nz/wbos/Index.aspx. Accessed 15 October 2013.

39. Smith M, Walker R, Canfell K (2013) National Cervical Screening Programme Annual Report (2010–2011). Wellington, NZ: National Screening Unit.

40. Ministry of Health (2012) Cancer: New registrations and deaths 2009. Wellington: Ministry of Health.

41. Ministry of Health (2011) Cancer: New registrations and deaths 2008. Wellington, New Zealand: Ministry of Health.

42. Ministry of Health (2014) Cancer: New registrations and deaths 2011. Wellington: Ministry of Health.

43. Ministry of Health (2010) Cancer: New registrations and deaths 2007. Wellington: Ministry of Health.

44. Ministry of Health (2010) Cancer: New registrations and deaths 2006. Wellington: Ministry of Health.

45. Ministry of Health (2009) Cancer: New Registrations and Deaths 2005 Revised edition. Wellington, New Zealand: Ministry of Health.

46. Ministry of Health (2013) Cancer: New Registrations and deaths 2010. Wellington: Ministry of Health.
47. New Zealand Health Information Service (2006) Cancer patient survival: Covering the period 1994–2003. Wellington, New Zealand: Ministry of Health.

48. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007) Human papillomavirus and cervical cancer. Lancet 370: 890–907. PMID: 17826171

49. Medical Services Advisory Committee (2014) MSAC Outcomes Public Summary Document: Application No. 1276 –Renewal of the National Cervical Screening Program. Available: http://www.m sac.gov.au/internet/msac/publishing.nsf/Content/FD36D6990FFAA639CA25799200058940/$File/1276%20-%20Final%20MSAC%20PSD%20-%20NCSP%20Renewal.pdf. Accessed 28 May 2015.

50. Duffy AP, Barrett DK, MA D (1999) Report of the Ministerial Inquiry into the Under-reporting of Cervical Smear Abnormalities in the Gisborne Region. Available: http://www.moh.govt.nz/notebook/nbbooks.nsf/0/a79b9e52f04d57e5cc256a9f006f1687/$FILE/csireport.pdf. Accessed 23 September 2015.

51. Committee of Inquiry into Allegations Concerning the Treatment of Cervical Cancer at National Women’s Hospital and into Other Related Matters (1988) The Report of the Cervical Cancer Inquiry 1988. Available: http://www.moh.govt.nz/notebook/nbbooks.nsf/0/64D0E19BA628E4FCC256E450001CC21/$file/The%20Cartwright%20Inquiry%201988.pdf. Accessed 22 June 2015.